Related Experiment Video
Updated: May 9, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Therapeutic Potential of Translational Readthrough at Disease-Associated Premature Termination Codons From Tumor
Leire Torices1, Caroline E Nunes-Xavier1,2,3, Rafael Pulido1,2,4
1Biobizkaia Health Research Institute, Barakaldo, Spain.
Abstract:
Tumor suppressor genes are frequently targeted by mutations introducing premature termination codons (PTC) in the protein coding sequence, both in sporadic cancers and in the germline of patients with cancer predisposition syndromes. These mutations have a high pathogenic impact since they generate C-terminal truncated proteins with altered stability and function. In addition, PTC mutations trigger transcript degradation by nonsense-mediated mRNA decay. Suppression of PTC by translational readthrough restores protein biosynthesis and stabilizes the PTC-targeted mRNA, making a suitable therapeutic approach the reconstitution of active full-length tumor suppressor proteins by pharmacologically-induced translational readthrough. Here, we review the recent advances in small molecule pharmacological induction of translational readthrough of disease-associated PTC from tumor suppressor genes, and discuss the therapeutic potential of translational readthrough in specific groups of patients with hereditary syndromic cancers.
Insights
Premature termination codons (PTCs) in tumor suppressor genes cause truncated proteins and mRNA decay. Pharmacological readthrough can restore full-length proteins, offering a potential cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Tumor suppressor genes frequently acquire premature termination codons (PTCs) in cancers and hereditary cancer syndromes.
- PTC mutations lead to truncated, unstable proteins and trigger mRNA degradation via nonsense-mediated decay.
Purpose of the Study:
- To review recent advances in small molecule-induced translational readthrough for PTCs in tumor suppressor genes.
- To discuss the therapeutic potential of this approach for hereditary syndromic cancers.
Main Methods:
- Review of literature on small molecule drugs that induce translational readthrough.
- Analysis of the impact of readthrough on protein restoration and mRNA stability.
- Discussion of clinical relevance for specific cancer predisposition syndromes.
Main Results:
- Pharmacological induction of translational readthrough can restore biosynthesis of full-length tumor suppressor proteins.
- This approach stabilizes PTC-targeted mRNA, counteracting nonsense-mediated decay.
- Small molecules show promise for treating cancers with specific PTC mutations.
Conclusions:
- Pharmacological translational readthrough is a promising therapeutic strategy for cancers with PTCs in tumor suppressor genes.
- This approach holds significant potential for patients with hereditary cancer syndromes.
- Further research can advance this strategy for clinical application.
Related Concept Videos
Translation
Translation Produces the Building Blocks of Life
Proteins are...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Leaky Scanning
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Improving Translational Accuracy

